STOCK TITAN

Cosmos Health (NASDAQ: COSM) awards Demetriades 20K shares, now holding 55K

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Cosmos Health Inc. director and secretary Demetrios G. Demetriades received an award of 20,000 shares of common stock at $0.283 per share as equity compensation. The grant came from the 2024 & 2025 Omnibus Incentive Plan, converting 20,000 vested RSUs into common shares and bringing his direct holdings to 55,000 shares.

Positive

  • None.

Negative

  • None.
Insider Demetriades Demetrios G.
Role Secretary
Type Security Shares Price Value
Conversion Restricted Stock Unit 20,000 $0.00 --
Grant/Award Common Stock, par value $.001 20,000 $0.283 $6K
Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct, null); Common Stock, par value $.001 — 55,000 shares (Direct, null)
Footnotes (1)
  1. Reflects the award of 20,000 shares of Common Stock granted on May 19, 2026, pursuant to the Issuer's 2024 & 2025 Omnibus Incentive Plan, in a transaction exempt under Rule 16b-3. The RSUs were granted on May 19, 2026, under the Issuer's 2024 & 2025 Omnibus Incentive Plan and vested on the date of the grant, in a transaction exempt under Rule 16b-3.
Equity grant size 20,000 shares Common stock awarded as compensation
Grant price per share $0.283 per share Recorded transaction price for common stock award
Post-transaction holdings 55,000 shares Direct common stock held after transactions
RSUs converted 20,000 RSUs Restricted Stock Units converted into common stock
RSU conversion price $0.00 per unit Conversion of RSUs into common stock
Restricted Stock Unit financial
"The 20,000 Restricted Stock Units were converted into 20,000 common shares"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Omnibus Incentive Plan financial
"under the Issuer's 2024 & 2025 Omnibus Incentive Plan and vested on the date"
An omnibus incentive plan is a single, flexible program a company uses to give employees and executives different types of pay tied to performance — for example stock options, restricted shares, cash bonuses and other awards — all governed by one set of rules. It matters to investors because it determines how many new shares may be created, how leaders are motivated and how much the company will spend on compensation over time; think of it as a master toolbox that affects both costs and the total share supply.
Rule 16b-3 regulatory
"in a transaction exempt under Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
derivative security financial
"Conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Demetriades Demetrios G.

(Last)(First)(Middle)
5 AG. GEORGIOU STR.

(Street)
PILEATHESSALONIKITK57001

(City)(State)(Zip)

GREECE

(Country)
2. Issuer Name and Ticker or Trading Symbol
Cosmos Health Inc. [ COSM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Secretary
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, par value $.00105/19/202605/19/2026A(1)20,000A$0.28355,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(2)05/19/202605/19/2026C20,00005/19/202605/19/2036Common Stock, par value $.00120,000$00D
Explanation of Responses:
1. Reflects the award of 20,000 shares of Common Stock granted on May 19, 2026, pursuant to the Issuer's 2024 & 2025 Omnibus Incentive Plan, in a transaction exempt under Rule 16b-3.
2. The RSUs were granted on May 19, 2026, under the Issuer's 2024 & 2025 Omnibus Incentive Plan and vested on the date of the grant, in a transaction exempt under Rule 16b-3.
/s/ Demetrios G. Demetriades06/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Cosmos Health (COSM) report for Demetriades?

Cosmos Health reported that director and secretary Demetrius G. Demetriades received an award of 20,000 common shares. These were issued as equity compensation by converting previously granted RSUs into common stock under the company’s 2024 & 2025 Omnibus Incentive Plan.

Was the Cosmos Health (COSM) insider transaction a market purchase or compensation grant?

The transaction was a compensation-related grant, not an open-market purchase. Demetriades received 20,000 common shares at $0.283 per share through the company’s 2024 & 2025 Omnibus Incentive Plan, reflecting a grant and RSU conversion exempt under Rule 16b-3.

How many Cosmos Health (COSM) shares does Demetriades hold after this Form 4?

After the reported transactions, Demetriades directly holds 55,000 Cosmos Health common shares. This total includes the 20,000 shares awarded upon conversion of his vested RSUs into common stock under the issuer’s 2024 & 2025 Omnibus Incentive Plan.

What happened to the 20,000 RSUs reported in the Cosmos Health (COSM) Form 4?

The 20,000 Restricted Stock Units were converted into 20,000 common shares at a $0.00 conversion price. The RSUs were granted and vested on May 19, 2026, under the 2024 & 2025 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3.

What is the value per share of the Cosmos Health (COSM) equity grant?

The equity grant to Demetriades is recorded at $0.283 per common share for 20,000 shares. This reflects the transaction price per share disclosed in the Form 4 for the non-derivative common stock received through the compensation award.

Under which plan were the Cosmos Health (COSM) RSUs and shares granted?

Both the RSUs and resulting common shares were granted under Cosmos Health’s 2024 & 2025 Omnibus Incentive Plan. The RSUs were granted and vested on May 19, 2026, and their conversion into common shares was reported as exempt under Rule 16b-3.